Recent Company News

• 07:38 AM ET Jun 26, 2025
  

  Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"

• 10:06 AM ET Jun 12, 2025
  

  InvestorNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights Growth and SEPA Funding Ahead of BIO 2025 CEO Participation

• 08:00 AM ET Jun 12, 2025
  

  Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

• 09:02 AM ET Jun 05, 2025
  

  Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

• 09:28 AM ET May 30, 2025
  

  BioMedNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q1 Revenue Growth Driven by CDMO Contracts, Net Loss Narrows

• 07:00 AM ET May 30, 2025
  

  Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

• 07:10 AM ET Jul 23, 2024
  

  Scinai Immunotherapeutics announces Positive Regulatory Feedback from PEI on path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb ($4.31, 0.00)

• 02:02 PM ET Mar 15, 2024
  

  StreetAccount Activist Summary: Week of 11-Mar

• 04:21 PM ET Mar 12, 2024
  

  Scinai Immunotherapeutics 12.96% shareholder Daniel Stone files 13D - 13D ($0.52, 0.00)

• 06:20 AM ET Jan 04, 2024
  

  Scinai Immunotherapeutics provides update on 2024 plans ($0.59, 0.00)